Elanco Animal Health vs Organon
ELAN and OGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELAN and OGN compare
Elanco Animal Health is the larger company, worth 3.2 times as much as Organon ($11.5B against $3.6B).
Elanco Animal Health grew revenue faster over the last twelve months (12.0% versus −3.2% for Organon).
Organon keeps more of each dollar of sales as profit, with a net margin of 3.5% compared with −4.0% at Elanco Animal Health.
Organon pays a dividend yielding 0.58%; Elanco Animal Health does not pay one.
Elanco Animal Health scores higher on the StockData Score (9 against 8 for Organon), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELAN | OGN |
|---|---|---|
| Size and price | ||
| Market cap | $11.5B | $3.6B |
| Share price | $23.06 | $13.84 |
| Change, 1 year | 2.1% | 118% |
| Change, 5 years | −32.4% | −61.9% |
| Beta (5Y) | 1.11 | 0.83 |
| Employees | 9,400 | 10K |
| StockData Score | ||
| Total score | 9 (better) | 8 |
| Valuation score | 1 | 2 (better) |
| Growth score | 3 (better) | 0 |
| Performance score | 3 (better) | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 18.0× |
| P/S | 2.3× | 0.6× (better) |
| P/B | 1.7× (better) | 3.0× |
| EV/EBITDA | 28.3× | – |
| P/FCF | 30.4× | 5.4× (better) |
| FCF yield | 3.3% | 18.6% (better) |
| Fair value | $10.92 | $14.66 |
| Margin of safety | −111% | 5.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.0% (better) | −3.2% |
| Revenue growth, 5Y average | 7.6% (better) | −0.99% |
| Net income growth (TTM) | −146% | −57.5% (better) |
| EPS growth (TTM) | −149% | −59.9% (better) |
| EPS growth, 5Y average | – | −39.0% |
| Profitability | ||
| Gross margin | 55.4% (better) | 53.1% |
| Net margin | −4.0% | 3.5% (better) |
| FCF margin | 7.5% | 11.1% (better) |
| Return on equity | −3.0% | 20.3% (better) |
| Financial health | ||
| Debt / equity | 0.59 (better) | 7.17 |
| Net debt / EBITDA | 6.43 | – |
| Current ratio | 2.05 (better) | 2.02 |
| Altman Z-score | 1.32 (better) | 1.03 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.58% |
| Payout ratio | – | 9.4% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.58% (better) |
| Ownership | ||
| Held by institutions | 113% | 83.3% |
| Held by insiders | 1.1% | 0.49% |
| Insider net buying, 12 months | $2.6M (better) | $301K |
| Short interest, % of float | 7.5% | 7.3% |
Go deeper
- ELAN stock overview
- ELAN income statement
- ELAN valuation and score
- OGN stock overview
- OGN income statement
- OGN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.